iRadimed Corporation $IRMD Shares Sold by Copeland Capital Management LLC

Key Points

• Copeland Capital Management trimmed its stake by 4.8% in Q4, selling 20,950 shares and now holds 412,550 shares (~3.24%, ~$40.1M); institutional investors own 92.34% of the stock and corporate insiders hold 36.8% with insiders selling 50,000 shares in the past three months.
• iRadimed beat Q4 estimates (EPS $0.54 vs. $0.49; revenue $22.69M vs. $21.60M) and issued Q1/FY2026 guidance (Q1: 0.440–0.480 EPS; FY: 2.060–2.210 EPS), while analysts have an average Buy rating and an average price target of $120.
• The company raised its quarterly dividend to $0.20 (annualized $0.80, ~0.9% yield), and the stock recently traded near $88.80 with a market cap of about $1.13B and a P/E around 50.7.

Copeland Capital Management LLC lessened its holdings in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 412,550 shares of the medical equipment provider's stock after selling 20,950 shares during the quarter. Copeland Capital Management LLC owned 3.24% of iRadimed worth $40,133,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC increased its position in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 211 shares in the last quarter. Quarry LP acquired a new stake in iRadimed during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC increased its position in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 495 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in iRadimed during the 3rd quarter worth approximately $47,000. Institutional investors and hedge funds own 92.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IRMD. Roth Mkm reissued a "buy" rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reissued a "buy" rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings reissued a "buy (b-)" rating on shares of iRadimed in a research report on Monday, December 29th. Finally, Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $120.00.

iRadimed Stock Down 1.5%

Shares of NASDAQ:IRMD opened at $88.80 on Friday. iRadimed Corporation has a 52-week low of $50.00 and a 52-week high of $107.90. The company has a 50 day moving average of $98.15 and a two-hundred day moving average of $93.46. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of 50.74 and a beta of 1.11.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The company had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, equities analysts anticipate that iRadimed Corporation will post 1.94 earnings per share for the current year.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. This is a positive change from iRadimed's previous quarterly dividend of $0.17. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed's dividend payout ratio is 45.71%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $100.04, for a total transaction of $500,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,250,000 shares in the company, valued at approximately $225,090,000. This represents a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 50,000 shares of company stock worth $4,877,850. Corporate insiders own 36.80% of the company's stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.